Inside the Pivotal Trials Shaping Vitiligo Treatment Choices

This episode, "Inside the Pivotal Trials Shaping Vitiligo Treatment Choices," features Dr. Rosmarin unpacking the design differences behind the pivotal topical and oral vitiligo trials.

Dr. Rosmarin compares the ruxolitinib cream pivotal Phase 3 program with the upadacitinib pivotal Phase 3 program, noting that both were well-designed, randomized, and well-executed, but differ in important ways. Inclusion criteria diverged: the topical program enrolled patients with up to ten percent body surface area, while the oral program required at least five percent, creating some population overlap but also substantial divergence, with the systemic study naturally including higher average involvement. Primary endpoints also differed. The topical cream trial measured F-VASI75 at twenty-four weeks as its regulatory endpoint, with T-VASI50 as a strong key secondary; by that point the study was no longer vehicle-controlled for a topical. The oral therapy trial used a co-primary endpoint of T-VASI50 and F-VASI75 measured at forty-eight weeks, a full year into treatment.

Dr. Rosmarin believes a meta-analysis focused specifically on the overlapping five-to-ten percent population could offer a more scientifically comparable efficacy assessment. Still, he cautions that the treated populations may not overlap as much as the raw percentages suggest, since clinical factors beyond BSA often determine which modality fits a given patient. Patients developing new lesions in additional locations, those with hard-to-reach areas like the shoulder blades, those with very high body surface area, or those with many small scattered spots may all be better suited to an oral agent regardless of their overall BSA. He also flags a methodological wrinkle: the topical cream trial ran during active COVID-19 transmission, so its adverse event profile shows more COVID-related events than the more recent oral therapy trial, complicating direct safety comparisons between the two programs.

In "How Trial Enrollment Criteria Shape Vitiligo Coverage Policy," Dr. Desai and Jason will examine how those trials' enrollment criteria are shaping coverage policy.